Clinical Trials Logo

Papillary Craniopharyngioma clinical trials

View clinical trials related to Papillary Craniopharyngioma.

Filter by:
  • None
  • Page 1

NCT ID: NCT03224767 Recruiting - Clinical trials for BRAF V600E Mutation Present

Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma

Start date: August 4, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well vemurafenib and cobimetinib work in treating patients with BRAF V600E mutation positive craniopharyngioma. Vemurafenib and cobimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.